Physician profile
Allison Raco
NPI 1548246606
$1,971.82
in general payments reported to CMS, 2019-2025
21 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $452 · 2023: $458 · 2024: $381 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $292.06 | 2021-2025 | |
| Abbvie INC. | $167.96 | 2021-2025 | |
| Leo Pharma INC. | $162.46 | 2021-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $150.98 | 2022-2025 | |
| Janssen Biotech, INC. | $142.64 | 2022-2024 | Remicade, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $137.12 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $101.48 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $93.70 | 2022-2025 | Ebglyss, Taltz |
| Incyte Corporation | $86.36 | 2022-2025 | Opzelura |
| Amgen INC. | $84.50 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $83.89 | 2021-2025 | |
| Galderma Laboratories, L.P. | $69.94 | 2023-2025 | Nemluvio |
| Pfizer INC. | $67.13 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Dermavant Sciences, INC. | $53.42 | 2022-2023 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.34 | 2025 | Vtama |
| Almirall LLC | $47.48 | 2021-2022 | |
| Ucb, INC. | $44.26 | 2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.67 | 2023 | |
| Celgene Corporation | $19.88 | 2024 | Sotyktu |
| Botanix Sb INC | $16.18 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Raco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.